Risk factors for distant recurrence in patients with rectal cancer supporting selection for total neoadjuvant therapy
DOI:
https://doi.org/10.2340/ao.v65.45169Keywords:
rectal neoplasm, neoadjuvant therapy,, radiotherapy, risk factorsAbstract
Background and purpose: In locally advanced rectal cancer, distant recurrence remains a major challenge. Total neoadjuvant therapy (TNT) has been implemented to reduce this risk. Identification of risk factors for distant recurrence to support selection of TNT is crucial to avoid excessive treatment. This study aimed to identify magnetic resonance imaging (MRI) features predictive of distant recurrence in patients with rectal cancer.
Material and methods: In this national retrospective cohort study, all patients were diagnosed with non-metastatic rectal cancer between 2016 and 2020 and received neoadjuvant radiotherapy followed by surgery. MRI features from the diagnostic report, including cT-stage, cN-stage, clinical extramural vascular invasion (cEMVI), distance to the mesorectal fascia (MRF), and tumor deposit, were registered. The primary endpoint was distant recurrence.
Results: A total of 648 patients were included in the study. In multivariate analysis using multiple imputation, risk factors significantly associated with distant recurrence were cT3c/cT3d/cT4-stage (hazard ratio [HR]: 1.8), cEMVI positive tumors (HR: 2.05), and cT3-stage tumors with a distance to MRF of ≤ 2 mm (HR: 1.51) compared with patients with cT1/cT2/cT3/cT3a/cT3b-stage, cEMVI negative tumors, and cT3-stage tumors with a distance to MRF > 2 mm, respectively. The cN-stage was not significantly associated with distant recurrence. Due to 67% missing data on tumor deposit status, the results regarding this feature cannot be considered conclusive.
Interpretation: In this study, cT-stage, cEMVI status, and distance to MRF are prognostic features for risk stratification for patients receiving neoadjuvant radiotherapy. These results may be used for selecting patients for future treatment strategies such as TNT.
Downloads
References
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.
https://doi.org/10.1016/S1470-2045(20)30555-6 DOI: https://doi.org/10.1016/S1470-2045(20)30555-6
Van Gijn W, Marijnen CAM, Nagtegaal ID, Kranenbarg EMK, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.
https://doi.org/10.1016/S1470-2045(11)70097-3 DOI: https://doi.org/10.1016/S1470-2045(11)70097-3
Ben Dhia S, Chauvière D, Mitrea D, Schiappa R, Pace Loscos T, Chamorey E, et al. Organ preservation, for rectal cancer: general overview of the latest data from phase III randomized trials. Acta Oncol. 2025;64:120–8.
https://doi.org/10.2340/1651-226X.2025.41057 DOI: https://doi.org/10.2340/1651-226X.2025.41057
Boute TC, Swartjes H, Greuter MJE, Elferink MAG, van Eekelen R, Vink GR, et al. Cumulative incidence, risk factors, and overall survival of disease recurrence after curative resection of stage II–III colorectal cancer: a population-based study. Cancer Res Commun. 2024;4(2):607–16.
https://doi.org/10.1158/2767-9764.CRC-23-0512 DOI: https://doi.org/10.1158/2767-9764.CRC-23-0512
Glimelius B, Myklebust TÅ, Lundqvist K, Wibe A, Guren MG. Two countries – two treatment strategies for rectal cancer. Radiother Oncol. 2016;121(3):357–63.
https://doi.org/10.1016/j.radonc.2016.11.010 DOI: https://doi.org/10.1016/j.radonc.2016.11.010
Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35:873-81.
https://doi.org/10.1016/j.annonc.2024.06.019 DOI: https://doi.org/10.1016/j.annonc.2024.06.019
Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali AM, et al. Total neoadjuvant therapy for rectal cancer: making sense of the results from the RAPIDO and PRODIGE 23 trials. Cancer Treat Rev. 2021;96(February):102177.
https://doi.org/10.1016/j.ctrv.2021.102177 DOI: https://doi.org/10.1016/j.ctrv.2021.102177
Jin J, Tang Y, Hu C, Jiang L ming, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol Clin Oncol. 2022;40(15):1681-692.
https://doi.org/10.1200/JCO.2021.39.15_suppl.3510 DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.3510
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15.
https://doi.org/10.1016/S1470-2045(21)00079-6 DOI: https://doi.org/10.1016/S1470-2045(21)00079-6
Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: ;ong-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–303.
https://doi.org/10.1093/annonc/mdz186 DOI: https://doi.org/10.1093/annonc/mdz186
Hofheinz RD, Fokas E, Benhaim L, Price TJ, Arnold D, Beets-Tan R, et al. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(9):1007–24.
https://doi.org/10.1016/j.annonc.2025.05.528 DOI: https://doi.org/10.1016/j.annonc.2025.05.528
Liu S, Jiang T, Xiao L, Yang S, Liu Q, Gao Y, et al. Total Neoadjuvant Therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1555–66.
https://doi.org/10.1002/onco.13824 DOI: https://doi.org/10.1002/onco.13824
Elm EV, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbrouckef JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;85(11):867–72. DOI: https://doi.org/10.2471/BLT.07.045120
https://doi.org/10.1136/bmj.39335.541782.AD DOI: https://doi.org/10.1136/bmj.39335.541782.AD
Klein MF, Gögenur I, Ingeholm P, Njor SH, Iversen LH, Emmertsen KJ, et al. Validation of the Danish Colorectal Cancer Group (DCCG.dk) database – on behalf of the Danish Colorectal Cancer Group. Colorectal Dis. 2020;22(12):2057–67.
https://doi.org/10.1111/codi.15352 DOI: https://doi.org/10.1111/codi.15352
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95(December 2018):103208.
https://doi.org/10.1016/j.jbi.2019.103208 DOI: https://doi.org/10.1016/j.jbi.2019.103208
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
https://doi.org/10.1016/j.jbi.2008.08.010 DOI: https://doi.org/10.1016/j.jbi.2008.08.010
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2025. Available from: https://www.R-project.org
van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.
https://doi.org/10.18637/jss.v045.i03 DOI: https://doi.org/10.18637/jss.v045.i03
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72–83.
https://doi.org/10.1093/annonc/mdx224 DOI: https://doi.org/10.1093/annonc/mdx224
Siddiqui MRS, Simillis C, Bhoday J, Battersby NJ, Mok J, Rasheed S, et al. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer. 2018;104:47–61.
https://doi.org/10.1016/j.ejca.2018.07.131 DOI: https://doi.org/10.1016/j.ejca.2018.07.131
Paul S, Arya S, Mokal S, Baheti A, Kumar S, Ramaswamy A, et al. Extra mural venous invasion as an independent prognostic marker in locally advanced rectal cancer: propensity score match pair analysis. Abdom Radiol. 2022;108(3):e592.
https://doi.org/10.1016/j.ijrobp.2020.07.1811 DOI: https://doi.org/10.1016/j.ijrobp.2020.07.1811
Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg. 2007;95(2):229–36.
https://doi.org/10.1002/bjs.5917 DOI: https://doi.org/10.1002/bjs.5917
Siddiqui MRS, Simillis C, Hunter C, Chand M, Bhoday J, Garant A, et al. A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. Br J Cancer. 2017;116(12):1513–9.
https://doi.org/10.1038/bjc.2017.99 DOI: https://doi.org/10.1038/bjc.2017.99
MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. Br Med J. 2006;333(7572):779–82.
https://doi.org/10.1136/bmj.38937.646400.55 DOI: https://doi.org/10.1136/bmj.38937.646400.55
Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol. 2008;47(1):20–31.
https://doi.org/10.1080/02841860701697720 DOI: https://doi.org/10.1080/02841860701697720
Fernandes MC, Gollub MJ, Brown G. The importance of MRI for rectal cancer evaluation. Surg Oncol. 2022;43(March):101739.
https://doi.org/10.1016/j.suronc.2022.101739 DOI: https://doi.org/10.1016/j.suronc.2022.101739
Zhang XY, Wang S, Li XT, Wang YP, Shi YJ, Wang L, et al. MRI of extramural venous invasion in locally advanced rectal cancer: relationship to tumor recurrence and overall survival. Radiology. 2018;289:677-85 https://doi.org/10.1148/radiol.2018172889 DOI: https://doi.org/10.1148/radiol.2018172889
Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol. 2024;42(28):3355–75.
https://doi.org/10.1200/JCO.24.01160 DOI: https://doi.org/10.1200/JCO.24.01160
Brouwer NPM, Stijns RCH, Lemmens VEPP, Nagtegaal ID, Beets-Tan RGH, Fütterer JJ, et al. Clinical lymph node staging in colorectal cancer; a flip of the coin? Eur J Surg Oncol. 2018;44(8):1241–6.
https://doi.org/10.1016/j.ejso.2018.04.008 DOI: https://doi.org/10.1016/j.ejso.2018.04.008
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Anna Baech Slipsager, Rana Bahij, Heidi Søgaard Christensen, Laura Vittrup Diness, Birgitte Mayland Havelund, Anne Ramlov, Signe Korsgaard Skriver, Joanna Eliza Szpejewska, Olga Tcacenco, Christian Thomsen, Laurids Østergaard Poulsen
This work is licensed under a Creative Commons Attribution 4.0 International License.
